Avid Bioservices Inc (CDMO)

[keep_trying]

Geo, your suggestion is one path that PPHM could explore. Gilead is not the only party moving forward a new treatment that might benefit from trials that include a Bavi arm.

It would be good information to have in hand if PPHM would track the patients that had been in their Ribavirin plus Bavi or Interferon study to see whether those showing a viral response during the study experienced a relapse or achieve a sustained viral response. That information ought to be available to PPHM, even if not part of the approved trial protocol.

Best wishes and IMO.
KT